ANGO News Alert Angiodynamics (ANGO) 16.86 11/13/2014 17:31:

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2014 at 6:31 PM

Angiodynamics (ANGO) 16.86 $ANGO

Thoratec (THOR) Down to Strong Sell on Growing Headwinds - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 12:20PM CST
On Nov 11, 2014, Zacks Investment Research downgraded Thoratec Corp. (THOR) to a Zacks Rank #5 (Strong Sell).
ABMD: 33.48 (-0.12), EW: 124.55 (+1.60), THOR: 28.40 (+0.48), ANGO: 16.86 (-0.12)

Abiomed (ABMD) Hits 52-Week High on Strong Q2 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 10:10AM CST
Shares of Abiomed, Inc. (ABMD) have been on the rise since it reported impressive second-quarter fiscal 2015 (ended Sep 30, 2014) results on Oct 30.
ABMD: 33.48 (-0.12), FLDM: 29.88 (-0.01), GMED: 22.92 (-0.24), ANGO: 16.86 (-0.12)

Mettler-Toledo (MTD) Tops Q3 Earnings on Revenue Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 8:34AM CST
Mettler-Toledo International Inc. (MTD) reported adjusted earnings per share (EPS) of $2.95 for the third quarter of fiscal 2014, which beat the Zacks Consensus Estimate of $2.86. Adjusted EPS also improved 13% from the year-ago quarter.
ABMD: 33.48 (-0.12), FLDM: 29.88 (-0.01), ANGO: 16.86 (-0.12), MTD: 290.03 (+5.33)

Roka Bioscience (ROKA) in Focus: Stock Surges 19.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:11AM CST
Roka Bioscience, Inc. (ROKA) was a big mover last session, as the company saw its shares rise over 19% on the day.
ABMD: 33.48 (-0.12), ROKA: 3.55 (-0.04), EW: 124.55 (+1.60), ANGO: 16.86 (-0.12)

AngioDynamics to Present at Upcoming Investor Conferences
GlobeNewswire - Tue Nov 11, 5:30AM CST
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today the company will present at the following investor conferences in November:
ANGO: 16.86 (-0.12)

Volcano Posts Narrower-than-Expected Q3 Loss, Guides Low - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 10:10AM CST
Despite Volcano (VOLC) provided disappointing revenue guidance for 2014 on account of expected negative foreign exchange impact, management expects accelerated profitability over the near term.
ABMD: 33.48 (-0.12), VOLC: 10.79 (-0.28), EW: 124.55 (+1.60), ANGO: 16.86 (-0.12)

Strength Seen in DexCom (DXCM): Stocks Gains 14.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 8:46AM CST
DexCom (DXCM) was a big mover last session, with shares rising over 14% on the day.
ABMD: 33.48 (-0.12), DXCM: 53.63 (-0.38), EW: 124.55 (+1.60), ANGO: 16.86 (-0.12)

Hologic Beats Q4 Earnings, Sales as All Segments Gain - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 1:50PM CST
Hologic (HOLX) entered into an amended license agreement with Roka Bioscience, which earned a one-time revenue benefit of $20.1 million for Hologic
ABMD: 33.48 (-0.12), DXCM: 53.63 (-0.38), ANGO: 16.86 (-0.12), HOLX: 26.52 (-0.03)

Thoratec Q3 Earnings & Revenues Lag Estimates, Down Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:00AM CST
Following the earnings release, shares of Thoratec Corp. (THOR) declined approximately 3.5% to close at $26.10 yesterday.
ABMD: 33.48 (-0.12), CYNO: 27.20 (-0.20), THOR: 28.40 (+0.48), ANGO: 16.86 (-0.12)

Foundation Medicine Slumps: FMI Tumbles 9.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:59AM CST
Foundation Medicine has been witnessing a flat trend in its current year earnings estimate and its share price has been falling for past 24 hours
ABMD: 33.48 (-0.12), DXCM: 53.63 (-0.38), FMI: 24.95 (-0.15), ANGO: 16.86 (-0.12)

Teleflex Beats on Q3 Earnings & Revenues, Outlook Raised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:20PM CST
Teleflex Inc (TFX) reported adjusted earnings of $1.57 per share which outshined both the Zacks Consensus Estimate of $1.37 and year-ago earnings of $1.33.
CYNO: 27.20 (-0.20), FLDM: 29.88 (-0.01), TFX: 114.64 (+0.17), ANGO: 16.86 (-0.12)

Symmetry Medical Q3 Earnings & Revenues Miss, Rise Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 1:10PM CST
Symmetry Medical Inc. (SMA) reported adjusted earnings per share of 11 cents in the third quarter of fiscal 2014, which missed the Zacks Consensus Estimates of 14 cents.
SMA: 9.48 (unch), CYNO: 27.20 (-0.20), FLDM: 29.88 (-0.01), ANGO: 16.86 (-0.12)

CryoLife Q3 Earnings Fall, Revenues Rise Y/Y; Shares Tank - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 1:00PM CST
CryoLife Inc. (CRY) reported adjusted earnings per share of 8 cents in the third quarter of fiscal 2014, lower than the year-ago earnings of 11 cents.
CYNO: 27.20 (-0.20), FLDM: 29.88 (-0.01), CRY: 9.74 (-0.16), ANGO: 16.86 (-0.12)

Mindray Medical Q3 Earnings in Line, 2014 View Lowered - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 2:07PM CST
Mindray Medical International Limited (MR) slashed its 2014 financial guidance in the face of increasing uncertainties in currency and other macro developments that could impact its performance in certain key markets.
ABMD: 33.48 (-0.12), FLDM: 29.88 (-0.01), ANGO: 16.86 (-0.12), MR: 31.22 (-0.27)

Techne Corp. (TECH) Q1 Earnings, Revenues Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 12:50PM CST
Techne Corp. (TECH) reported adjusted earnings of 85 cents per share in the first quarter fiscal 2015, which was lower than the Zacks Consensus Estimate of 87 cents.
CYNO: 27.20 (-0.20), FLDM: 29.88 (-0.01), TECH: 92.10 (+0.08), ANGO: 16.86 (-0.12)

Abiomed Tops Q2 Earnings, Revenues; FY15 Sales View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 12:10PM CST
Abiomed Inc. (ABMD) reported second-quarter fiscal 2015 earnings of 9 cents per share, outshining the Zacks Consensus Estimate of 2 cents.
ABMD: 33.48 (-0.12), FLDM: 29.88 (-0.01), BEAT: 8.17 (-0.10), ANGO: 16.86 (-0.12)

Becton, Dickinson (BDX) Beats Q4 Earnings, Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 11:03AM CST
Becton, Dickinson and Company (BDX) reported fourth-quarter fiscal 2014 earnings of $1.68 per share, which beat the Zacks Consensus Estimate by 3 cents.
BDX: 129.31 (-0.04), FLDM: 29.88 (-0.01), BEAT: 8.17 (-0.10), ANGO: 16.86 (-0.12)

Accuray (ARAY) Q1 Loss Wider Than Expected, Revenues Lag - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 12:30PM CST
Accuray Inc (ARAY) reported a loss of 28 cents per share in the first quarter of fiscal 2015, wider than the Zacks Consensus Estimate of a loss of 13 cents and a year-ago loss of 21 cents.
ATEC: 1.36 (-0.06), CYNO: 27.20 (-0.20), ARAY: 7.07 (+0.02), ANGO: 16.86 (-0.12)

Greatbatch Beats Q3 Earnings Estimates; Upgrades '14 View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 9:10AM CDT
Based on its third-quarter results, the addition of CCC Medical Devices, and the forecast for the fourth quarter, Greatbatch raised its full-year 2014 revenue and adjusted earnings per share guidance.
ATEC: 1.36 (-0.06), CYNO: 27.20 (-0.20), GB: 49.67 (-0.52), ANGO: 16.86 (-0.12)

Luminex (LMNX) Upgraded to Strong Buy on Impressive Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 5:25PM CDT
Luminex Corporation (LMNX) posted encouraging third-quarter 2014 numbers on Oct 27, with adjusted earnings surpassing the Zacks Consensus Estimate by a wide margin of 120%.
ATEC: 1.36 (-0.06), CYNO: 27.20 (-0.20), LMNX: 18.33 (-0.18), ANGO: 16.86 (-0.12)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Nanoscope Therapeutics Aims for Eye-Catching Advances

Gearing Up for a Boston Showcase Nanoscope's High-Stakes Boston Rendezvous In a move set to grab some serious eyeballs, Nanoscope Therapeutics is geared up to strut their stuff at Advanced Therapies USA 2026 in Boston. Scheduled for November 4–5 at the Hynes Convention Center, the event isn't just another pitstop—it's a billboard for what these guys have cooking. With...

Benewake Unveils SR Series LiDAR for Mobile Robots

Wave Goodbye to Bulky Sensors Hot off the Beijing press, Benewake's got something new—the SR Series 360° 3D LiDARs, set to stir up the robotics world. They're compact, power-efficient, and packed with smarts. It seems Benewake is tapping into a juicy market with these little sensors. Sleek Design and Big Promises The SR18 and SR96 models have a lot going for them. The...

Del Monte Faces Class Action Over Major Data Breach

Data Breach Fallout Looms Over Del Monte Here's the scoop on Del Monte Foods facing what looks like a data breach debacle of epic proportions. Ransomware has hit the fan, and now folks are scrambling as Edelson Lechtzin LLP gears up to lay down some serious class action heat. From Cyber Shadows to Court Considerations This storm brewed on February 7, 2026. Del Monte’s...

Cooper's Stock Takes a Beating: What's Behind It?

A Shock to the System: Cooper's Rough Patch Not every day you see a stock take a body slam like this! Cooper Companies (NASDAQ: COO) got walloped after revealing some unsavory truths about its Q3 2026 performance. The market didn't just flinch—it reeled. On September 10, 2026, COO shares dove a steep $9.31—around a 14.6% free fall—whacking off over $1.7 billion in...

Data Incident at Killingly Schools: Lessons in Security

Caught off Guard in Connecticut When a school district's name crosses the ticker tape, you don't expect it to be about a data breach. But that's the hand Killingly Public Schools in Connecticut was dealt. Despite bulletproofing their systems, they found themselves up against a nasty cyber skirmish — a breach exposing personally identifiable information. Timeline of...

Union Pride: Built To Last® Premieres Season 10

Midwest union pride is surging again, this time with the launch of the tenth season of Built To Last® on Halloween Day. It’s like they chose this date to remind us that these builders are the spine of infrastructure we take for granted—spooky how easy it is to overlook their contributions. Spotlighting Union Excellence This isn't just another construction show;...

MacGregor Revamps Fleet for Wallenius Wilhelmsen Deal

MacGregor's Big Move: Retrofitting 35 Vessels I'll tell you something right off the bat—the maritime industry's always got some sea changes brewing, but this latest one’s a real head-turner. MacGregor, those wizards of heavy machinery, have sealed a deal to retrofit 35 ships for Wallenius Wilhelmsen. We’re talking a serious overhaul here, folks, with programmable...

HanchorBio's Trispecific Strategy Boosts HCB303's Prospects

Rethinking the Anti-TIGIT Game with HCB303 There's a fresh breeze blowing in the realm of immunotherapy, and it comes courtesy of HanchorBio's innovative trispecific approach. Now, for those of us who've been unimpressed by the underwhelming returns from anti-TIGIT trials, this new development might just stir the pot. HanchorBio's got the green light not only from the...

Mazu Culture Forum Unveils New Initiatives in China

A Cultural Tapestry Unfurls in Putian Picture this: a kaleidoscope of cultures and ideas unraveling in the coastal city of Putian. The 11th Global Mazu Culture Forum kicks off on October 31, bringing together minds—both fresh and seasoned—from an impressive array of 47 countries and regions. It's more than a forum; it's a vibrant crossroads of innovation, tradition,...

VIZ Media Expands Reach with MangaPlaza Partnership

Manga Magic in the Digital Space Another day, another expansion, folks. VIZ Media's latest move to have its manga offerings available on MangaPlaza feels like a pretty shrewd play in the fierce arena of digital content. Who'd have thought decades ago that we'd be sitting here talking about digital comics like they’re the next Netflix? VIZ Media's expansion into...